New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for ...

Signs of cognitive decline may include poor oral motor performance, a new study finds. Testing to see if a person can alternate between opposing oral muscle movements could help spot cognitive decline ...

At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found in 6 of 283 participants (2.1%) who received long-acting therapy and in 7 of 283 (2.5%) who received oral therapy ...